Miami, Florida – Global Stem Cells Group (GSCG) is delighted to announce the successful registration of its Cellgenic Lyophilized Exosomes line throughout the entire region of the United Arab Emirates (UAE). This significant achievement marks a pivotal moment for both GSCG and the field of regenerative medicine in the UAE, facilitating greater access to advanced therapeutic options for healthcare professionals and patients alike.

Exosomes, extracellular vesicles secreted by cells, have garnered considerable attention in regenerative medicine due to their ability to carry bioactive molecules that modulate various cellular functions critical for tissue repair and regeneration. The Cellgenic Exosomes, now available to practicing doctors in the United Arab Emirates, represent a cutting-edge advancement in this field.

The registration of Cellgenic Lyophilized Exosomes in the UAE not only empowers healthcare professionals with a powerful therapeutic tool but also streamlines distribution logistics. Unlike traditional exosome products that require stringent refrigeration during transport, the lyophilized formulation can be shipped and stored at ambient temperatures, enhancing accessibility even in regions with challenging infrastructure.

Benito Novas, Founder of the Global Stem Cells Group, expressed his enthusiasm, stating, “With the registration of this groundbreaking exosome product, Global Stem Cells Group reaffirms its commitment to advancing regenerative medicine in the region. We are dedicated to providing healthcare professionals with innovative solutions that can transform patient care and outcomes.”

Dave Christensen, CEO of Global Stem Cells Group, echoed these sentiments, emphasizing the significance of this achievement in expanding the reach of regenerative medicine. “The registration of Cellgenic Lyophilized Exosomes in the UAE represents a significant milestone in our mission to commercialize access to cutting-edge therapies worldwide. We are proud to contribute to the advancement of healthcare in this region and beyond,” he remarked.

Global Stem Cells Group continues to demonstrate rapid growth and innovation, with a global network of offices and a steadfast commitment to driving progress in regenerative medicine. The registration of Cellgenic Lyophilized Exosomes in the UAE further solidifies GSCG’s position as a leader in the field, poised to deliver transformative solutions to patients worldwide.

About Cellgenic

Cellgenic is a distinguished brand renowned for its cellular products and kits featuring the latest advancements in regenerative medicine, including Exosomes, Collagenase, PRP, Wharton’s jelly mesenchymal cells, and more. Committed to excellence in research and development, Cellgenic strives to provide healthcare professionals with cutting-edge technologies of the highest quality to enhance patient care and outcomes.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements

Miami, Florida– Global Stem Cells Group is pleased to announce the official registration of its Cellgenic Lyophilized Exosomes line throughout the region of Uzbekistan. This significant milestone allows doctors and distributors in Uzbekistan to access and utilize the two Lyophilized Exosomes product lines, specifically tailored for aesthetic and orthopedic applications.

Utilizing cutting-edge exosome technology, the Cellgenic Lyophilized Exosomes involve the freeze-drying of extracellular vesicles (EVs) separately from mesenchymal stem cell cultures expanded in the laboratory. These Lyophilized Exosomes, reconstituted with saline just before use, have proven to be highly effective in reducing inflammation and managing pain.

An outstanding feature of the Lyophilized Exosomes is their global shipping capability without the need for refrigeration. This eliminates logistical challenges related to temperature requirements, ensuring easy access to various locations without constraints. Global Stem Cells Group has prioritized versatility, addressing common limitations faced by many medications.

Uzbekistan will now have access to both presentations of Cellgenic Lyophilized Exosomes. The aesthetic line, primarily utilized by aesthetic doctors and dermatologists, and the orthopedic “the Rege series,” dedicated to pain management and sports medicine. This expansion in product availability underscores Global Stem Cells Group’s commitment to providing innovative solutions that overcome challenges and meet diverse medical needs.

Experiencing Unprecedented Growth

Global Stem Cells Group is on an impressive growth trajectory with multiple offices worldwide. The company is dedicated to expanding its outreach by opening offices wherever it is prudent to do so. The recent product registration in the region is expected to further strengthen GSCG’s position as a global leader in the regenerative and restorative medicine space.

Consolidating Presence in Uzbekistan

GSCG is solidifying its presence in Uzbekistan with the inauguration of a clinic and training center in Tashkent in 2023. Now, in 2024, the company marks the beginning of the year with the registration of its successful product line, Cellgenic Exosomes, promising stability and recognition in Uzbekistan and neighboring countries.

Benito Novas, CEO of Global Stem Cells Group, expressed his enthusiasm for the company’s growth, stating: “Our goal at Global Stem Cells Group is to make available to all doctors and patients the latest technologies in Regenerative Medicine. I am very pleased that Uzbekistan has joined us. Now, we not only have a point to treat patients and train doctors, but they can also benefit from cellgenic exosomes, which are part of the latest technologies revolutionizing the field of regenerative medicine.”

About Cellgenic

Cellgenic is a brand of cellular products and kits equipped with the latest technologies in the regenerative medicine market, including Exosomes, Collagenase, PRP, Wharton’s jelly mesenchymal cells, and more. Constantly engaged in research, Cellgenic aims to provide doctors and patients with the latest technologies of the highest quality.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements

MIAMI, Florida – January 29, 2024 – The International Society for Stem Cell Application (ISSCA), a globally recognized leader in Regenerative Medicine, is delighted to announce its forthcoming regenerative medicine conference in Termez city, Republic of Uzbekistan. The theoretical conference is scheduled to take place on March 4-5, 2024, at the conference hall of the International Research Center Imam Termeziy.

ISSCA has established a strategic partnership with the Ministry of Health of the Republic of Uzbekistan, specifically the Termez branch of Tashkent Medical Academy (Ozbekiston Respublikasi Sogliqni Saqlash Vazirligi), to organize this impactful event. This collaboration exemplifies the shared commitment of ISSCA and the Ministry of Health to advancing healthcare through the dissemination of knowledge in the field of regenerative medicine in the region.

The primary objective of the conference is to bring together experts from diverse backgrounds in regenerative medicine, fostering collaboration between science and practice. Distinguished foreign scientists specializing in regenerative medicine, cell therapy applications in degenerative diseases, transplantation, traumatology, dermatology, neuroimmune diseases, and rehabilitation will be in attendance.

Key Focus Areas of the Conference Program:

A panel of esteemed experts on stem cells and regenerative medicine will feature at the conference. They will conduct a two-day rigorous research-based discussion on the vital topic covering stem cells and regenerative medicine.

World-class medical experts in regenerative medicine will share their skills and experience during the theoretical session. The conference will feature esteemed speakers from Turkey, Uzbekistan, and the USA.

The conference will focus on a wide range of topics, including:

• Regenerative medicine – the need for knowledge in various fields of medicine
• Exosomes/ Extracellular Vesicles
• Mesenchymal stem/stromal cells
• Hematopoietic stem/progenitor cells and engineering
• Gene editing/Gene therapy
• Immunotherapy (CAR-Ts, T Reg, NK cells, etc.)
• Tissue engineering
• Embryonic, organ, and other tissue-specific stem cells
• Application of biomedical cell products in organ and tissue transplantation
• Immunologic aspects of cell therapy for human diseases
• Knowledge in the field of the application of mesenchymal stromal cells in medical practice

What the ISSCA Organization has to say:

Dr. Salih Yildirim, ISSCA president, expressed his eagerness to share his expertise, stating, “Regenerative medicine is a fast-paced field experiencing exponential growth with ongoing research and product advancements worldwide. We are thrilled to collaborate with the Termez branch of Tashkent Medical Academy to host this conference.”

Benito Novas, Founder of Global Stem Cells Group and head of public relations at ISSCA, added, “ISSCA’s mission is to share regenerative medicine’s benefits worldwide, supporting patients and physicians in harnessing its power globally.”

The conference expects to be a unique platform for knowledge exchange, collaboration, and advancements in the field of regenerative medicine. ISSCA invites professionals, researchers, and enthusiasts to join this groundbreaking event in the pursuit of enhancing global healthcare through cutting-edge regenerative medicine practices.

For more information, please visit ISSCA Conference – Tashkent, March 2024.

Final Words About the Conference:

Regenerative medicine is rapidly growing with continuous explorations revealing new protocols and products. The conference aims to keep participants updated with the industry’s most recent changes and advancements, empowering them to explore more opportunities and be part of a valuable stem cell community.

Learn more about ISSCA and advancements in stem cell therapy by visiting our website or emailing us at info@stemcellsgroup.com.

About the Termiz Branch of the Tashkent Medical Academy:

Established in 2018, the Termiz branch of the Tashkent Medical Academy aims to produce highly skilled medical professionals meeting global standards. Committed to academic excellence, the branch offers opportunities for teachers to obtain scientific degrees through research, conducting doctoral dissertations, and anticipates a progressive increase in research activities, solidifying its role in shaping Uzbekistan’s healthcare future.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA), a distinguished division of the Global Stem Cells Group (GSCG), is delighted to unveil its much-anticipated international symposium on Regenerative Medicine and Cellular Therapies. This groundbreaking event is set to take place in the vibrant city of Cancún, México, over three days, from June 14th to 16th, 2024, with one day dedicated to conferences and the subsequent two days featuring hands-on sessions.

A Global Gathering of Scientific Minds

The symposium aims to bring together leading scientists and medical professionals from around the world, providing an unparalleled platform to explore and discuss the latest advancements in regenerative medicine. With elite speakers, including renowned scientists and physicians with extensive experience in the field, attendees are expected to gain unique insights into the cutting-edge clinical applications of stem cell therapies.

Key Highlights of the Symposium

• Stay Ahead with the Latest Technologies:

Attendees will be at the forefront of breakthrough technologies in regenerative medicine. Learn about the most recent advancements that are reshaping the landscape of healthcare and discover how these technologies may elevate your practice and patient care.

• Explore Cutting-Edge Products and Equipment:

Gain firsthand insights into the latest products and equipment driving the field of stem cell therapy. From state-of-the-art medical devices to groundbreaking tools, discover innovations that may enhance your clinical practice and contribute to better patient outcomes.

• Delve into Tissue Engineering:

Tissue engineering is a frontier where science meets medical marvels. Attendees will have the opportunity to delve into the intricacies of tissue engineering, understanding how it is revolutionizing regenerative medicine and paving the way for transformative treatments.

• Comprehensive Understanding of Regenerative Medicine:

Broaden your understanding of regenerative medicine as a whole. From foundational principles to cutting-edge applications, the symposium provides a comprehensive overview, equipping attendees with the knowledge needed to excel in this rapidly evolving field.

• Network with Industry Leaders and Peers:

Connect with a diverse and dynamic community of professionals, including doctors, researchers, innovators, and decision-makers. Engage in meaningful conversations, forge collaborations, and build a network that extends beyond the symposium, providing ongoing support and insights.

• Acquire Practical Knowledge from Hands-On Training:

Beyond theoretical insights, the symposium offers invaluable hands-on training sessions led by ISSCA-certified instructors. Gain practical experience in the aesthetic and clinical applications of stem cell therapy, ensuring you leave with skills ready for immediate implementation.

• Navigate Regulatory:

Stay informed on the latest regulatory and ethical considerations in stem cell technology. Navigate the complexities of compliance while gaining insights into how to address challenges in a rapidly evolving regulatory landscape.

• Stay Informed on Marketing Trends:

Learn about modern technologies that can enhance your marketing efforts in the field of regenerative medicine. Stay ahead of the curve with insights into effective strategies to promote your practice and reach a wider audience.

In short, the ISSCA International Symposium is not just an event; it is an immersive experience that seeks to empower attendees with the knowledge, skills and connections needed to shape the future of regenerative medicine. Join us in Cancun, Mexico, and be a catalyst for positive change in the medical landscape.

For registration and additional information, please contact:

Email: info@stemcellsgroup.com

Phone: +1305 560 5337

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

The International Society for the Application of Stem Cells presents the schedule of International Cellular therapy certifications for 2024.

Miami, Florida – ISSCA, the International Society for Stem Cell Application and the Educational Division of Global Stem Cells Group, a global leader in cellular therapies and regenerative medicine education, proudly unveils its 2024 schedule for upcoming training dates in multiple countries. In alignment with ISSCA’s mission to extend the benefits of regenerative medicine to all, the organization invites the participation of physicians interested in advancing their expertise in the field.

ISSCA’s commitment to advancing regenerative medicine is exemplified by providing participants with exclusive access to the latest cutting-edge technologies in biologics and regenerative medicine products.

Participants are expected to learn valuable insights into the practical applications of these technologies and acquire knowledge on how regenerative medicine can contribute to addressing contemporary medical challenges, ultimately enhancing patient care.

ISSCA’s comprehensive training program comprises a one-day theoretical segment in which participants learn the fundamentals of cell therapies. It includes discussions on relevant cases and technologies. The practical part encourages participants to apply these therapies on real patients, a portion that lasts from one to two days depending on the ISSCA educational program in the country of the training. Technologies covered include exosomes, umbilical cord stem cells (where permitted), bone marrow and fat stem cells, PRP, and various alternative therapies.

These certifications are meticulously designed for physicians and specialists seeking to expand their knowledge of regenerative medicine and integrate diverse cell therapies into their medical practices.

Key Training Dates for 2024:

• Cancun, Mexico: February 9, 10, and 11
• Istanbul, Turkey: February 23 and 24
• Buenos Aires, Argentina: March 8 & 9
• Cancun, Mexico: March 22, 23, and 24
• Brussels, Belgium: March 29 and 30
• Cancun, Mexico: April 5, 6, and 7
• Lisbon, Portugal: April 12 and 13
• Fort Lauderdale, USA: April 19 and 20
• Santo Domingo, Dominican Republic: May 3 & 4
• Dubai, UAE: May 17-18
• Istanbul, Turkey: May 24-25
• Cancun, Mexico: June 14, 15, and 16
• Buenos Aires, Argentina: June 28-29
• Istanbul, Turkey: July 5 and 6
• Cancun, Mexico: August 9-10-11

For more information on ISSCA certifications and to make reservations, visit https://www.issca.us/, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

ISSCA is the educational division of Global Stem Cells Group, serving as a multidisciplinary community of scientists and physicians aspiring to treat disease and diminish human suffering through advances in the science, technology, and practice of regenerative medicine. ISSCA serves its members through advances made in the specialty of regenerative medicine.

ISSCA offers certification training in cities around the world, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty. The mission is to promote quality and consistency in regenerative medicine worldwide.

About Global Stem Cells Group:

Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company utilizes its network to provide leadership in regenerative medicine education, research, and patient applications.

GSCG’s mission is to enable physicians to present the benefits of stem cell medicine to patients worldwide. The company also collaborates with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company under the symbol MSSV. https://finance.yahoo.com/quote/mssv/.

For more information about Global Stem Cells Group, Inc. companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Global Stem Cells Group (GSCG) and ReGen are thrilled to announce the grand opening of a new franchise clinic in Tashkent, Uzbekistan. The inauguration ceremony, attended by distinguished leaders in the field of regenerative medicine, marks a momentous occasion for healthcare in the region.

The event was graced by the presence of Dr. Salih Yildirim, Director of ReGen and President of the International Society for Stem Cell Application (ISSCA), and Benito Novas, the Director of Public Relations for both GSCG and ISSCA.

In addition to celebrating the clinic’s opening, the Tashkent center hosted the first ISSCA training program in the region, providing local physicians with the latest advancements in regenerative medicine.

Dr. Salih Yildirim expressed his delight, stating, “After inaugurating clinics in Istanbul (Turkey), Buenos Aires (Argentina), Cancun (Mexico), Miami (USA), and Jakarta (Indonesia), we are now here in Uzbekistan, in Tashkent. This moment fills me with great joy and a profound sense of purpose. It is a privilege to bring the benefits of regenerative medicine to the people of Uzbekistan”

Benito Novas added, “This is impressive. In the field of regenerative medicine, we aim to expand the movement, benefiting not only local patients but patients worldwide. This will undoubtedly be a great success. Regenerative medicine is not just the medicine of the future; it’s the medicine of the present.”

The newly established center will also serve as a training hub for ISSCA, contributing to the enhancement of knowledge and expertise among healthcare professionals in the region.

Partnership Between Global Stem Cells Group and ReGen

Through their strategic partnership, ReGen has experienced remarkable growth, leveraging Global Stem Cells Group’s reputation and extensive resources to open state-of-the-art clinics in several countries. These clinics have become pioneers in regenerative care in the region.

ReGen is at the forefront of introducing cutting-edge aesthetic treatments, such as the perfected hair transplant technique from Turkey, revolutionizing the regenerative healthcare landscape. Patients now have access to the latest and most effective treatment options. This partnership underscores Global Stem Cells Group’s vision to make its exceptional services accessible to people around the world.

While ReGen brings access to clinics, advanced techniques and expertise, Global Stem Cells Group provides valuable resources as a conglomerate of companies engaged in product manufacturing and comprehensive training through ISSCA. This collaboration has the potential to change the lives of people seeking regenerative care on a global scale.

This landmark partnership is poised to reshape the world of regenerative care, marking a transformative moment for the field of regenerative medicine.

For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

About ReGen

ReGen is a highly acclaimed Turkish company with clinics in Turkey and in several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

For further information, please contact:

investor.relations@mssvinc.com

Telephone: (800) 956-3935

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is pleased to announce a new date for practical certification at the highly anticipated 2023 World Congress of Regenerative Medicine in Istanbul, Turkey. Due to the overwhelming demand for clinical experience with real patients, ISSCA has extended the event, providing doctors with an extra day of hands-on training.

The original three-day event, scheduled from November 10 to 12, 2023, includes two days of stimulating conferences and lectures on November 10 and 11, conducted by distinguished physicians from around the world. This covers subjects pertinent to basic science, current advancements, and clinical experiences.

Due to an unprecedented response, the hands-on clinical experience day, November 12, is already at full capacity for the initial package subscribers. However, ISSCA has made the prudent decision to open a new date for training on November 13, 2023. This additional date offers an opportunity for new participants to benefit from valuable hands-on experience while also participating in the two days of conferences on November 10 and 11.

To facilitate a comprehensive understanding of the training and certification programs offered during the World Congress, ISSCA has launched a dedicated website showcasing agendas for various days and different package options. For more information, please visit https://www.issca.us/turkey-world-conference-2023/.

What to Expect at the ISSCA World Congress of Regenerative Medicine

The ISSCA World Congress of Regenerative Medicine serves as a global platform for the advancement of cellular therapies, related technologies, and clinical applications. This annual gathering brings together eminent scientists and physicians from over 30 countries for three days of conferences, lectures, and hands-on clinical application workshops.

Key focus areas for this year’s event include:

• Molecular Biology
• New treatment models in surgical and cosmetic applications
• The latest innovations in regenerative Medicine

Furthermore, the conference will explore the legal implications of regenerative medicine practices worldwide.

A Transformative Experience

The ISSCA 2023 World Congress in Istanbul is a must-attend event for all those interested in regenerative medicine. Focused on innovation, collaboration and knowledge sharing, the congress expects to be a transformative experience for scientists, physicians and healthcare professionals from around the world.

For more information about the November 10 to 13 ISSCA World Congress 2023, please visit our official website today.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is delighted to announce its strategic partnership with the Turkish Stem Cell Society, along with the prestigious endorsement of three of Turkey’s top universities: Yeditepe University,  Atlas University and Marmara University. This collaboration marks a significant milestone in advancing the field of regenerative medicine and stem cell therapy in Turkey and beyond.

The annual Congress of Regenerative Medicine, scheduled to take place from November 10 to 12, 2023, will be hosted at the elegant Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey. This event is poised to serve as a pivotal platform for the exchange of groundbreaking advancements in stem cell therapy and regenerative medicine.

Partnership with Turkish Stem Cell Society and University Endorsements

The partnership with the Turkish Stem Cell Society underscores the commitment of ISSCA to advancing the field of regenerative medicine not only on a global scale but also within the vibrant Turkish scientific and medical community. Turkish Stem Cell Society has been at the forefront of research and innovation in stem cell therapy, making this collaboration a natural fit to foster greater knowledge sharing and cooperation.

Furthermore, ISSCA is honored to be endorsed by three of the most prestigious universities in Turkey:

Yeditepe University: Yeditepe University, a leading academic institution in Turkey, has a rich history of contributing to the fields of medicine and healthcare. Its endorsement of the Regenerative Medicine World Congress 2023 reaffirms the importance of this event in advancing the understanding of regenerative medicine.

Atlas University: Atlas University, with its commitment to research and innovation, plays a pivotal role in shaping the future of healthcare in Turkey. The university’s endorsement signifies the importance of regenerative medicine in modern medical practices.

Marmara University: Marmara University, recognized for its commitment to excellence in education, research, and innovation, is yet another prestigious institution supporting the congress. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has become a center of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure collaborate with Global Stem Cells Group to drive advances in regenerative medicine within the center, which is located on the university’s main campus.

World Congress Highlights

Representing over 35 countries, the Regenerative Medicine World Congress 2023 is set to be a hub of medical expertise. Renowned doctors and scientists from around the globe are expected to converge to share their insights and findings through evidence-based research presentations. This three-day symposium is designed to reshape medical understanding and ignite innovative possibilities.

A key feature of the congress is the immersive hands-on training, provided by ISSCA-certified instructors. Participants are expected to have the opportunity to delve into clinical and aesthetic applications of stem cell therapy over a single intensive day. This specialized training, guided by experts with extensive experience, equips attendees with practical skills that can be directly applied in their medical practice.

Collaboration and Appreciation

ISSCA is thrilled about the collaborative partnership with the Turkish Stem Cell Society and deeply appreciates the endorsements from Yeditepe University, Atlas University, and Marmara University. We look forward to the Regenerative Medicine World Congress 2023 as a significant step towards advancing the field of regenerative medicine. Your support and participation are invaluable, and we are genuinely excited to embark on this journey together.

For more information about the Regenerative Medicine World Congress 2023 and to register for this groundbreaking event, please visit www.issca.com

About the Turkish Stem Cell Society:

The Turkish Stem Cell Society is a leading organization dedicated to promoting ethical and responsible stem cell research and therapy in Turkey. They are committed to advancing scientific knowledge and education in the field of stem cells and regenerative medicine.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.